IN2014DN09352A - - Google Patents

Info

Publication number
IN2014DN09352A
IN2014DN09352A IN9352DEN2014A IN2014DN09352A IN 2014DN09352 A IN2014DN09352 A IN 2014DN09352A IN 9352DEN2014 A IN9352DEN2014 A IN 9352DEN2014A IN 2014DN09352 A IN2014DN09352 A IN 2014DN09352A
Authority
IN
India
Prior art keywords
compounds
disorders
substituents
useful
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628669&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09352(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014DN09352A publication Critical patent/IN2014DN09352A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN9352DEN2014 2012-06-20 2013-06-17 IN2014DN09352A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661953P 2012-06-20 2012-06-20
PCT/EP2013/062463 WO2013189865A1 (en) 2012-06-20 2013-06-17 N-aryltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
IN2014DN09352A true IN2014DN09352A (pt) 2015-07-17

Family

ID=48628669

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9352DEN2014 IN2014DN09352A (pt) 2012-06-20 2013-06-17

Country Status (22)

Country Link
US (1) US20150133512A1 (pt)
EP (1) EP2864301A1 (pt)
JP (1) JP2015520203A (pt)
KR (1) KR20150011389A (pt)
CN (1) CN104395299A (pt)
AU (1) AU2013279513A1 (pt)
BR (1) BR112014030674A2 (pt)
CA (1) CA2869564A1 (pt)
CL (1) CL2014003241A1 (pt)
CO (1) CO7131357A2 (pt)
EA (1) EA201492281A1 (pt)
HK (1) HK1206339A1 (pt)
IL (1) IL236087A0 (pt)
IN (1) IN2014DN09352A (pt)
MA (1) MA37762B1 (pt)
MX (1) MX2014014711A (pt)
PE (1) PE20142305A1 (pt)
PH (1) PH12014502363A1 (pt)
SG (1) SG11201407228PA (pt)
UA (1) UA110310C2 (pt)
WO (1) WO2013189865A1 (pt)
ZA (1) ZA201408167B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
TW201437200A (zh) * 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
CA2953472C (en) 2014-06-27 2022-08-02 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN107721984A (zh) * 2017-11-07 2018-02-23 大连理工大学 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法
CN107827829A (zh) * 2017-11-07 2018-03-23 大连理工大学 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法
US11261180B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as LPA antagonists
CN111479807A (zh) 2017-12-19 2020-07-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑吖嗪
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
MX2020005323A (es) 2017-12-19 2020-08-13 Bristol Myers Squibb Co Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
KR20200100753A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아졸
TW201927778A (zh) 2017-12-19 2019-07-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸***唑類
US11312706B2 (en) 2017-12-19 2022-04-26 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as LPA antagonists
WO2019126099A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
CN112041302A (zh) 2017-12-19 2020-12-04 百时美施贵宝公司 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸
ES2962367T3 (es) 2017-12-19 2024-03-18 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
CA3158743A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
IL298082A (en) 2020-06-03 2023-01-01 Gilead Sciences Inc lpa receptor antagonists and uses thereof
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
AU2011338561A1 (en) * 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
US8975235B2 (en) * 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013189864A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-alkyltriazole compounds as lpar antagonists

Also Published As

Publication number Publication date
EA201492281A1 (ru) 2015-04-30
MA37762B1 (fr) 2018-04-30
JP2015520203A (ja) 2015-07-16
KR20150011389A (ko) 2015-01-30
PE20142305A1 (es) 2015-01-16
MA37762A1 (fr) 2017-07-31
CA2869564A1 (en) 2013-12-27
ZA201408167B (en) 2015-12-23
UA110310C2 (uk) 2015-12-10
BR112014030674A2 (pt) 2017-06-27
CO7131357A2 (es) 2014-12-01
EP2864301A1 (en) 2015-04-29
HK1206339A1 (en) 2016-01-08
CL2014003241A1 (es) 2015-03-20
MX2014014711A (es) 2015-03-04
CN104395299A (zh) 2015-03-04
SG11201407228PA (en) 2014-12-30
PH12014502363A1 (en) 2015-01-12
US20150133512A1 (en) 2015-05-14
WO2013189865A1 (en) 2013-12-27
IL236087A0 (en) 2015-02-01
AU2013279513A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
IN2014DN09352A (pt)
IN2014DN09348A (pt)
IN2014DN09347A (pt)
PH12016500024A1 (en) Bromodomain inhibitor
IN2014MN02598A (pt)
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
IN2015DN01119A (pt)
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
IN2014DN09434A (pt)
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
MX2016002794A (es) Compuestos antiproliferativos.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
IN2014DN06869A (pt)
MX340574B (es) Imidazo pirazinas.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
IN2013DN02555A (pt)
WO2015002755A3 (en) Compounds for the treatment of malaria
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
MX2014001862A (es) 5-cicloalquil-o 5-heterociclil-nicotinamidas.